Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of Major Adverse Events (MAEs)
Timeframe: 30 days
Technical success
Timeframe: 24 hours
Stent graft patency
Timeframe: 12 months
Aneurysm rupture
Timeframe: 12 months
Absence of Type I and III endoleak through 12 months;
Timeframe: 12 months
Absence of stent fractures in the attachment zone through 12 months
Timeframe: 12 months
Absence of open or endovascular secondary interventions
Timeframe: 12 months
Absence of aneurysm expansion (> 5 mm diameter increase)
Timeframe: 12 months
Absence of stent-graft migration
Timeframe: 12 months